Ironwood Pharma's (IRWD) Linzess Sales Missed Estimates; Leerink Partners Reiterates Market Perform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. QGEN
7. CSX
8. LRCX
9. NDAQ
10. BFH

Go back to Ironwood Pharma's (IRWD) Linzess Sales Missed Estimates; Leerink Partners Reiterates Market Perform

Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update

November 3, 2015 4:05 PM EST

LINZESS® (linaclotide) prescriptions increased approximately 38% to over 550 thousand in third quarter 2015 compared to third quarter 2014

LINZESS U.S. net sales increased approximately 47% to $117.5 million in third quarter 2015 compared to third quarter 2014

Ironwood revenue increased approximately 134% to $39.6 million in third quarter 2015 compared to third quarter 2014

Multiple positive development milestones including linaclotide 72mcg Phase III data, initiation of Phase IIb linaclotide colonic release trial, and advancement of sGC platform

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More

Ironwood Pharmaceuticals Initiates Clinical Studies of Soluble Guanylate Cyclase Stimulators IW-1973 and IW-1701

November 3, 2015 8:02 AM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the initiation of a Phase Ib clinical study of IW-1973 and a Phase Ia clinical study of IW-1701, both of which are investigational soluble guanylate cyclase (sGC) stimulators from within a broad, pharmacologically-distinct library of sGC compounds... More

Ironwood and Allergan Initiate Phase IIb Clinical Trial of Linaclotide Colonic Release in Adults with Irritable Bowel Syndrome with Constipation

November 2, 2015 8:03 AM EST

CAMBRIDGE, Mass. & DUBLIN--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today the initiation of a Phase IIb... More